Mark Mapstone

Picture of Mark Mapstone
Professor, Neurology
School of Medicine
Vice Chair for Research, Neurology
School of Medicine
Chief, Neuropsychology Division, Neurology
School of Medicine
Faculty, Institute for Memory Impairments and Neurological Disorders (UCI MIND)
Fellow, Center for the Neurobiology of Learning and Memory
Co-Director, Center for Aging Research in Down Syndrome (CFAR-DS)
Ph.D., Northwestern University, 2000, Clinical Psychology
M.A., Boston University, 1990, Psychology
B.S., Hobart College, 1989, Psychology
Phone: (949) 824-7184
Email: mark.mapstone@uci.edu
University of California, Irvine
318 Sprague Hall
839 Health Sciences Road
Mail Code: 3910
Irvine, CA 92697
Research Interests
Cognitive Phenotyping, Biomarkers of Neurological Disease, Cognitive Neuroscience
Appointments
2000-2002, Post-doctoral Fellow, Clinical Neuropsychology, University of Rochester School of Medicine
2002-2008, Assistant Professor, Neurology, University of Rochester School of Medicine
2008-2015, Associate Professor, Neurology, University of Rochester School of Medicine
Research Abstract
I am a translational neuroscientist. My goal is to translate discoveries about the aging brain into practical and implementable approaches for successful cognitive aging at the individual level. My current work is focused on early detection of age-related neurological disease especially Alzheimer’s disease and Parkinson’s disease using careful cognitive phenotyping and biomarkers obtained from blood. We are using this information to develop screening tools that can be used to enrich clinical trials with appropriate subjects for disease modifying interventions. We hope to develop reliable biomarkers for clinical use.
Awards and Honors
1996, University Scholar, The Graduate School, Northwestern University
1998, Fellow, Buehler Center on Aging, Northwestern University Medical School
2000, George Yacorzinski Scholar, Northwestern University Medical School
2001, NIH Post-doctoral Fellowship, University of Rochester
2003, NIH Career Development Award (K23)
2004, John Henry Hobart Fellow in Ethics and Social Justice, Hobart College
2020, Sigma Xi, International Scientific Research Honor Society
Publications
Publications for past 3 years (2020-2023)

1. Chen Q., Baran TM, Rooks B, O’Banion MK, Mapstone M, Zhang Z, and Lin FV. (2020). Cognitively supernormal older adults maintain a unique structural connectome that is resistant to Alzheimer’s pathology, NeuroImage: Clinical, 28,102413. PMID: 33134477.

2. Yilmaz A, Ustun I, Ugur Z, Hu WT, Fiandaca MS, Mapstone M, Federoff HJ, Maddens M, and Graham SF. (2020). A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer’s Disease.78(4):1381-1392. doi: 10.3233/JAD-200305. PMID: 33164929.

3. Mapstone M, Gross TJ, Macciardi F, Cheema AK, Head E, Handed BL, Klunk WE, Christian BT, Silverman W, Lott IT, Schupf N for the ABC-DS (2020). Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down Syndrome. Alzheimer’s & Dementia: Diagnosis and Disease Monitoring. 12(1):e12028. PMID: 32258359.

4. Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott IT, Rafii MS, Handen BL, Klunk WE, Head E, Christian BT, Foroud T, Lai F, Rosas DH, Zaman S, Ances B, Wang M-C, Tycko B, Lee JH, and O’Bryant S, (2020). Proteomic Profiles for Alzheimer’s Disease and Mild Cognitive Impairment Among Adults with Down Syndrome Spanning Serum and Plasma: An ABC-DS Study. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 12 (1): e12039. PMID: 32626817.

5. Handen BL, Lott IT, Christian BT, Schupf N, O’Bryant S, Mapstone M, Fagan AM, Lee J, Tudorascu D, Wang MC, Head E, Klunk W, Ances B, Lai F, Zaman S, Krinsky-McHale S, Brickman AM, Rosas HD, Cohen A, Andrews H, Hartley S, Silverman W, and for the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS). (2020). The Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS): Rationale and Methodology. Alzheimer’s & Dementia: Diagnosis and Disease Monitoring. PMID: 32775597.

6. Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas DH Zaman S, Petersen ME, Strydom A, Fortea J, Handen B, and O’Bryant S, Ph.D. (2020). The A/T/N Framework for Alzheimer's Disease in Adults with Down Syndrome. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.

7. Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale S., Mapstone M, Silverman W, Lott, I, Klunk W, Head E, Christian B, Foroud T, Lai F, Rosas HD, Zaman S, Wang M-C, Tycko B, Lee J, Handen B, Hartley S, Fortea J, & O’Bryant SE; for the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) (2021). Plasma total-tau and Neurofilament light chain (Nf-L) as diagnostic biomarkers of Alzheimer’s disease dementia and mild cognitive impairment in adults with Down syndrome. Journal of Alzheimer’s Disease. 79(2):671-681.PMID: 33337378.

8. Fote G, Wu J, Mapstone M, Macciardi F, Fiandaca MS, Federoff HJ. (2021). Plasma Sphingomyelins in Late-Onset Alzheimer's Disease. J Alzheimer’s Dis. 83(3):1161-1171. PMID: 34397408.

9. Hampel H, Nisticò R, Seyfried NT, Levey AI, Modeste E, Lemercier P, Baldacci F, Toschi N, Garaci F, Perry G, Emanuele E, Valenzuela PL, Lucia A, Urbani A, Sancesario GM, Mapstone M, Corbo M, Vergallo A, Lista S; Alzheimer Precision Medicine Initiative (APMI). Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Res Rev. 69:101346. PMID: 33915266.

10. Rajagopal MU, Bansal S, Kaur P, Jain SK, Altadil T, Hinzman CP, Li Y, Moulton J, Singh B, Bansal S, Chauthe SK, Singh R, Banerjee PP, Mapstone M, Fiandaca MS, Federoff HF, Unger K, Smith JP, and Cheema AK. (2021). TGFß Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFß Induced EMT in PDAC. Cancers. 13(24):6204. PMID:34944824.

11. O'Bryant, SE, Zhang, F, Petersen, M, Hall JB, Johnson LA, Yaffe K, Mason D, Braskie M, Barber RA, Rissman RA, Mapstone M, Mielke MM, Toga QW, for the HABLE Study Team. (2022). A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimer's Dement. 18(1):77-87. PMID: 34057802.

12. Queder, N, Phelan, MJ, Taylor, L, Tustison N, Doran E, Hom C, Nguyen D, Lai F, Pulsifer M, Price J, Kreisl WC, Rosas HD, Krinsky-McHale S, Brickman AM, Yassa MA, Schupf N, Silverman W, Lott IT, Head E, Mapstone M, Keator DB, for the Alzheimer's Biomarkers Consortium. (2022). Joint-label fusion brain atlases for dementia research in Down syndrome. Alzheimer's Dement. 14(1):e12324. PMID: 35634535.

13. Macciardi F, Giulia Bacalini M, Miramontes R, Boattini A, Taccioli C, Modenini G, Malhas R, Anderlucci L, Gusev Y, Gross TJ, Padilla RM, Fiandaca MS, Head E, Guffanti G, Federoff HJ, & Mapstone M. (2022). A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease. GeroScience 44(3):1525–1550. PMID: 35585302.

14. Hartley SL, Fleming V, Piro-Gambetti B, Cohen A, Ances BM, Yassa MA, Brickman AM, Handen BL, Head E, Mapstone M, Christian BT, Lott IT, Doran E, Zaman S, Krinsky-McHale S, Schmitt FA, Hom C, Schupf N; ABC-DS Group. Impact of the COVID 19 pandemic on daily life, mood, and behavior of adults with Down syndrome. Disabil Health J. 2022 Feb 17:101278. doi: 10.1016/j.dhjo.2022.101278. Epub ahead of print. PMID: 35256308.

15. Martini AC, Gross TJ, Head E, and Mapstone M. (2022). Beyond Amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer’s disease in people with Down syndrome. Neuron. 110(13):2063-2079. PMID: 35472307

16. Janelidze S, Christian BT, Price J, Laymon C, Schupf N, Klunk WE, Lott I, Silverman W, Rosas HD, Zaman S, Mapstone M, Lai F, Ances BM, Handen BL, Hansson O. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. 2022 Aug 1;79(8):797-807. doi: 10.1001/jamaneurol.2022.1740. PMID: 35789365.

17. Parkin GM, Kim S, Mikhail A, Malhas R, McMillan L, Hollearn M, Granger DA, Mapstone M, Yassa MA, Thomas EA. Associations between saliva and plasma cytokines in cognitively normal, older adults. Aging Clin Exp Res. 2023 Jan;35(1):117-126. doi: 10.1007/s40520-022-02292-9. Epub 2022 Nov 1. PMID: 36319939.

18. Dunham SJB, McNair KA, Adams ED, Avelar-Barragan J, Forner S, Mapstone M, Whiteson KL. Longitudinal Analysis of the Microbiome and Metabolome in the 5xfAD Mouse Model of Alzheimer's Disease. mBio. 2022 Dec 5;13(6):e0179422. doi: 10.1128/mbio.01794-22. Epub ahead of print. PMID: 36468884.

19. Fleming V, Helsel BC, Ptomey LT, Rosas HD, Handen B, Laymon C, Christian BT, Head E, Mapstone M, Lai F, Krinsky-McHale S, Zaman S, Ances BM, Lee JH, Hartley SL; and the Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS) Consortium. Weight Loss and Alzheimer's Disease in Down Syndrome. J Alzheimers Dis. 2022 Dec 19. doi: 10.3233/JAD-220865. Epub ahead of print. PMID: 36565120.

20. Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant S, Lai F, Rosas HD, Lee JH, Silverman W, Brickman AM, Chhatwal JP, Cruchaga C, Perrin RJ, Xiong C, Hassenstab J, McDade E, Bateman RJ, Ances BM; Alzheimer's Biomarker Consortium-Down Syndrome; Dominantly Inherited Alzheimer Network. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2023 Jan;22(1):55-65. doi: 10.1016/S1474-4422(22)00408-2. PMID: 36517172.
Grants
R01 AG058644 (Principal Investigator) Multi-omic Investigation of Exercise Effects in MCI
U19 AG068054 (Principal Investigator) The Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS)
U54 AG05439 (Co-Investigator) UC Irvine MODEL-AD
R01 AG056726 (Co-Investigator) Visceral fat, neuroinflammation and brain health: Towards early detection and prevention of preclinical dementia
R01 AG065314 (Co-Investigator) Brain ERPs to assess emotional function in normal aging and MCI/AD
U19 AG078109 (Co-Investigator) Health and Aging Brain Study-Health Disparities (HABS-HD)
Professional Societies
Society for Neuroscience
International Neuropsychology Society
American Academy of Neurology
Alzheimer’s Association, International Society to Advance Alzheimer's Research and Treatment (ISTAART)
International Trisomy 21 Research Society
Graduate Programs
Interdepartmental Neuroscience Program
Research Centers
Center for Aging Research in Down Syndrome (CFAR-DS)
Last updated
01/25/2023